Patent Tracker
Applications for patents related to psychedelics have boomed in recent years. Nonprofits, pharmaceutical companies, startups, and academic institutions are all jockeying to patent specific psychedelic compounds and formulations. To help keep tabs on the status of patent applications as they wind their way through the U.S. Patent and Trademark’s review process, BCSP has collaborated on a patent tracker with Psychedelic Alpha, an independent media outlet, community and consultancy firm in the psychedelic field, and Calyx Law, a patent law boutique focusing on cannabis and psychedelics related IP. Read more about the history and process of psychedelic patents here.
662 Patents
MDMA
Title
Enantiomeric ratios of 3,4-methylenedioxymethamphetamine and related metabolites and uses thereof
Subject Matter
Compositions comprising (R)-MDMA or a pharmaceutically acceptable salt thereof with no or substantially no (S)-MDMA, pharmaceutically acceptable salt thereof, or metabolite thereof. Also provided herein are methods of using the compositions for treating diseases/disorders, e.g., PTSD.
MDMA
Title
Synthesis of mdma or its optically active (r)- or (s)-mdma isomers
Subject Matter
Compositions comprising (R)-MDMA or a pharmaceutically acceptable salt thereof with no or substantially no (S)-MDMA, pharmaceutically acceptable salt thereof, or metabolite thereof. Also provided herein are methods of using the compositions for treating diseases/disorders, e.g., PTSD.
Psilocybin
Title
Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
Subject Matter
Psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell.
Ibogaine
Title
Methods and compositions for preparing and purifying noribogaine
Subject Matter
Methods and compositions for purifying the non-addictive alkaloid noribogaine.
Ibogaine
Title
Compositions for reducing appetite and craving, increasing satiety, enhancing mood, and reducing stress
Subject Matter
Compositions which reduce craving for unhealthy foods, sweetened beverages and confections, nicotine-containing products, or alcohol without causing undesired physical or psychological side effects, while simultaneously enhancing mood and reducing stress.
Ibogaine
Title
Controlled release compositions for modulating free-radical induced damage and methods of use thereof
Subject Matter
Compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition.
Owner
University of California; Otonomy
Patent Number
US9,427,472B2Priority Date
07.21.2008
Status
Granted
Psilocybin
Title
Esters of indoles
Subject Matter
Discloses, with coinventor Franz Troxler, the first laboratory synthesis of psilocybin and various analogues; claims novel analogues.
DMT
Title
Method of treating mucosal inflammation
Subject Matter
Methods of treating mucosal inflammation in the gastrointestinal tract, by administering 5-HT7 receptor antagonist, including N,N-DMT
Ibogaine
Title
Bioactive tricyclic ibogaine analogs
Subject Matter
Ibogaine analogs are provided, which are phenyl-substituted-hexahydroazepino[4,5-b]indoles useful to treat cocaine addiction and the use of other addictive substances.
Owner
Regents of the University of Minnesota; University of Miami
Patent Number
US5,616,575APriority Date
12.04.1995
Status
Granted
Psilocybin
Title
Psilocybin compositions
Subject Matter
Methods and compositions for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
Page 1 of 67